Literature DB >> 17415632

A meta-analysis of antibiotic therapy for active ulcerative colitis.

Roja Rahimi1, Shekoufeh Nikfar, Ali Rezaie, Mohammad Abdollahi.   

Abstract

To systematically evaluate the efficacy of antibacterial therapy in ulcerative colitis, we carried out a meta-analysis of controlled clinical trials. Within the time period 1966 through September 2006, PUBMED, EMBASE, and SCOPUS were searched for clinical trial studies that investigated the efficacy of antibiotics in ulcerative colitis. We considered clinical remission as our key outcome of interest. Of 122 studies, 10 randomized placebo-controlled clinical trials matched our criteria and were included in the analysis (530 patients). All the studies used antibiotics as an adjunct therapy to conventional treatment of ulcerative colitis (i.e., corticosteroids and 5-aminosalycilic acid). Pooling of these trials yielded odds ratio (OR) of 2.14 (95% confidence interval [CI], 1.48-3.09; P<0.0001) in favor of antimicrobial therapy. Meta-analysis of short-term trials (5-14 days) showed a higher rate of clinical remission in patients treated with antibiotics (OR, 2.02; 95% CI, 1.36-3). These results suggest that adjunctive antibacterial therapy is effective for induction of clinical remission in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17415632     DOI: 10.1007/s10620-007-9760-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis.

Authors:  E Parlak; U Dağli; A Ulker; C Alkim; B Sahin
Journal:  J Clin Gastroenterol       Date:  2001-07       Impact factor: 3.062

Review 2.  Antibiotics and probiotics in treatment of inflammatory bowel disease.

Authors:  Paolo Gionchetti; Fernando Rizzello; Karen-M Lammers; Claudia Morselli; Lucia Sollazzi; Samuel Davies; Rosy Tambasco; Carlo Calabrese; Massimo Campieri
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy.

Authors:  T Nomura; T Ohkusa; I Okayasu; T Yoshida; M Sakamoto; H Hayashi; Y Benno; S Hirai; M Hojo; O Kobayashi; T Terai; H Miwa; Y Takei; T Ogihara; N Sato
Journal:  Aliment Pharmacol Ther       Date:  2005-04-15       Impact factor: 8.171

Review 4.  Environmental risk factors in inflammatory bowel disease.

Authors:  I Koutroubakis; O N Manousos; S G Meuwissen; A S Pena
Journal:  Hepatogastroenterology       Date:  1996 Mar-Apr

5.  Rifaximin systemic absorption in patients with ulcerative colitis.

Authors:  F Rizzello; P Gionchetti; A Venturi; M Ferretti; S Peruzzo; X Raspanti; M Picard; N Canova; E Palazzini; M Campieri
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

6.  Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.

Authors:  R W Chapman; W S Selby; D P Jewell
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

7.  Oral tobramycin in ulcerative colitis: effect on maintenance of remission.

Authors:  A J Lobo; D A Burke; G M Sobala; A T Axon
Journal:  Aliment Pharmacol Ther       Date:  1993-04       Impact factor: 8.171

8.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

9.  A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.

Authors:  G J Mantzaris; K Petraki; E Archavlis; P Amberiadis; D Kourtessas; A Christidou; G Triantafyllou
Journal:  Scand J Gastroenterol       Date:  2001-09       Impact factor: 2.423

Review 10.  Etiology and pathophysiology of inflammatory bowel disease--environmental factors.

Authors:  T Andus; V Gross
Journal:  Hepatogastroenterology       Date:  2000 Jan-Feb
View more
  28 in total

Review 1.  A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease.

Authors:  Roja Rahimi; Mohammad Reza Shams-Ardekani; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2010-09-28       Impact factor: 5.742

Review 2.  Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future?

Authors:  Arthur Kaser; Sebastian Zeissig; Richard S Blumberg
Journal:  Dig Dis       Date:  2010-09-30       Impact factor: 2.404

3.  Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

4.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

5.  Rifaximin in the treatment of inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

6.  Dietary phenethylisothiocyanate attenuates bowel inflammation in mice.

Authors:  Moul Dey; Peter Kuhn; David Ribnicky; Vummidigiridhar Premkumar; Kenneth Reuhl; Ilya Raskin
Journal:  BMC Chem Biol       Date:  2010-04-27

Review 7.  Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2008-08-06       Impact factor: 3.199

Review 8.  On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies.

Authors:  Roja Rahimi; Shilan Mozaffari; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2008-07-10       Impact factor: 3.199

Review 9.  Use of rifaximin in gastrointestinal and liver diseases.

Authors:  Rani H Shayto; Rachel Abou Mrad; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

10.  On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials.

Authors:  Behzad Elahi; Shekoufeh Nikfar; Saeed Derakhshani; Mohammad Vafaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2007-10-17       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.